Startseite News
News

Isatuximab + carfilzomib–dexamethasone: a new standard of care for R/R MM

21-06-2021 08:58

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, et al.

The study authors conclude that the addition of isatuximab to carfilzomib–dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population.

ABSTRACT IN LANCET

 

Zurück

Einen Kommentar schreiben

Sie müssen sich anmelden, um Kommentare hinzuzufügen.